The aminothiol redox status in haemodialysis patients does not improve with folate therapy

References

• Raine A. E., Margreiter R., Brunner F. P., Ehrich J. H., Geerlings W., Landais P., Loirat C., Mallick N. P., Selwood N. H., Tufveson G., et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992; 7: 7–35
   PubMed Web of Science ®Google Scholar
• Bostom A. G., Culleton B. F. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999; 10: 891–900
   PubMed Web of Science ®Google Scholar
• Himmelfarb J., Stenvinkel P., Ikizler T. A., Hakim R. M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524–38
   PubMed Web of Science ®Google Scholar
• Jacobsen D. W. Hyperhomocysteinemia and oxidative stress: time for a reality check?. Arterioscler Thromb Vasc Biol 2000; 20: 1182–4
   PubMed Web of Science ®Google Scholar
• Harrison D., Griendling K. K., Landmesser U., Hornig B., Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91: 7A–11A
   PubMed Web of Science ®Google Scholar
• Moustapha A., Gupta A., Robinson K., Arheart K., Jacobsen D. W., Schreiber M. J., Dennis V. W. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int 1999; 55: 1470–5
   PubMedGoogle Scholar
• Ducloux D., Klein A., Kazory A., Devillard N., Chalopin J. M. Impact of malnutrition‐inflammation on the association between homocysteine and mortality. Kidney Int 2006; 69: 331–5
   PubMed Web of Science ®Google Scholar
• Van den Berg M., Boers G. H., Franken D. G., Blom H. J., Van Kamp G. J., Jakobs C., Rauwerda J. A., Kluft C., Stehouwert C. D. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25: 176–81
   PubMed Web of Science ®Google Scholar
• Chao C. L., Kuo T. L., Lee Y. T. Effects of methionine‐induced hyperhomocysteinemia on endothelium‐dependent vasodilation and oxidative status in healthy adults. Circulation 2000; 101: 485–90
   PubMed Web of Science ®Google Scholar
• Ueland P. M., Refsum H., Beresford S. A., Vollset S. E. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000; 72: 324–32
   PubMed Web of Science ®Google Scholar
• Chambers J. C., Ueland P. M., Wright M., Dore C. J., Refsum H., Kooner J. S. Investigation of relationship between reduced, oxidized, and proteinbound homocysteine and vascular endothelial function in healthy human subjects. Circ Res 2001; 89: 187–92
   PubMed Web of Science ®Google Scholar
• Li H., Lewis A., Brodsky S., Rieger R., Iden C., Goligorsky M. S. Homocysteine induces 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase in vascular endothelial cells: a mechanism for development of atherosclerosis?. Circulation 2002; 105: 1037–43
   PubMed Web of Science ®Google Scholar
• Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocys‐teinemia and its impact on endothelial function. Curr Drug Metab 2005; 6: 27–36
   PubMed Web of Science ®Google Scholar
• Ueland P. M. Homocysteine species as components of plasma redox thiol status. Clin Chem 1995; 41: 340–2
   PubMed Web of Science ®Google Scholar
• Apeland T., Mansoor M. A., Seljeflot I., Bronstad I., Goransson L., Strandjord R. E. Homocysteine, malondialdehyde and endothelial markers in dialysis patients during low‐dose folinic acid therapy. J Intern Med 2002; 252: 456–64
   PubMedGoogle Scholar
• Mansoor M. A., Svardal A. M., Schneede J., Ueland P. M. Dynamic relation between reduced, oxidized, and protein‐bound homocysteine and other thiol components in plasma during methionine loading in healthy men. Clin Chem 1992; 38: 1316–21
   PubMedGoogle Scholar
• Mansoor M. A., Svardal A. M., Ueland P. M. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 1992; 200: 218–29
   PubMed Web of Science ®Google Scholar
• Ueland P. M., Mansoor M. A., Guttormsen A. B., Muller F., Aukrust P., Refsum H., Svardal A. M. Reduced, oxidized and protein‐bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status – a possible element of the extracellular antioxidant defense system. J Nutr 1996; 126: 1281S–4S
   PubMed Web of Science ®Google Scholar
• Andersson A., Lindgren A., Arnadottir M., Prytz H., Hultberg B. Thiols as a measure of plasma redox status in healthy subjects and in patients with renal or liver failure. Clin Chem 1999; 45: 1084–6
   PubMed Web of Science ®Google Scholar
• Di Giuseppe D., Di Simplicio P., Capecchi P. L., Lazzerini P. E., Pasini F. L. Alteration in the redox state of plasma in heart‐transplant patients with moderate hyperhomocysteinemia. J Lab Clin Med 2003; 142: 21–8
   PubMedGoogle Scholar
• Hultberg B., Andersson A., Arnadottir M. Reduced, free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure. Nephron 1995; 70: 62–7
   PubMedGoogle Scholar
• Van Tits L., De Graaf J., Hak‐Lemmers H., Bredie S., Demacker P., Holvoet P., Stalenhoef A. Increased levels of low‐density lipoprotein oxidation in patients with familial hypercholesterolemia and in end‐stage renal disease patients on hemodialysis. Lab Invest 2003; 83: 13–21
   PubMed Web of Science ®Google Scholar
• Hasselwander O., Young I. S. Oxidative stress in chronic renal failure. Free Radic Res 1998; 29: 1–11
   PubMed Web of Science ®Google Scholar
• Himmelfarb J., McMenamin E., McMonagle E. Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int 2002; 61: 705–16
   PubMed Web of Science ®Google Scholar
• Palleschi S., De Angelis S., Rossi B., Diana L., Papa V., Severini G., Splendiani G. Homocysteinemia correlates with plasma thiol redox status in patients with end‐stage renal disease. Nephron Clin Pract 2008; 108: c106–12
   Google Scholar
• Cianciolo G., La Manna G., Coli L., Donati G., D'Addio F., Persici E., Comai G., Wratten M., Dormi A., Mantovani V., Grossi G., Stefoni S. 5‐Methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients. Am J Nephrol 2008; 28: 941–8
   PubMedGoogle Scholar
• Zou C. G., Banerjee R. Homocysteine and redox signaling. Antioxid Redox Signal 2005; 7: 547–59
   PubMed Web of Science ®Google Scholar
• Mansoor M. A., Bergmark C., Svardal A. M., Lonning P. E., Ueland P. M. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early‐onset peripheral vascular disease. Homocysteine and peripheral vascular disease. Arterioscler Thromb Vasc Biol 1995; 15: 232–40
   PubMedGoogle Scholar
• Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?. Lancet 1994; 344: 721–4
   PubMed Web of Science ®Google Scholar
• Ghezzi P., Bonetto V. Redox proteomics: identification of oxidatively modified proteins. Proteomics 2003; 3: 1145–53
   PubMed Web of Science ®Google Scholar
• Apeland T., Froyland E. S., Kristensen O., Strandjord R. E., Mansoor M. A. Drug‐induced pertubation of the aminothiol redox‐status in patients with epilepsy: Improvement by B‐vitamins. Epilepsy Res 2008, In press
   PubMedGoogle Scholar
• Vianna A. C., Mocelin A. J., Matsuo T., Morais‐Filho D., Largura A., Delfino V. A., Soares A. E., Matni A. M. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int 2007; 11: 210–16
   PubMedGoogle Scholar
• Jamison R. L., Hartigan P., Kaufman J. S., Goldfarb D. S., Warren S. R., Guarino P. D., Gaziano J. M. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end‐stage renal disease: a randomized controlled trial. J Am Med Assoc 2007; 298: 1163–70
   PubMed Web of Science ®Google Scholar
• Suliman M. E., Filho J. C., Barany P., Anderstam B., Lindholm B., Bergstrom J. Effects of methionine loading on plasma and erythrocyte sulphur amino acids and sulph‐hydryls before and after co‐factor supplementation in haemodialysis patients. Nephrol Dial Transplant 2001; 16: 102–10
   PubMedGoogle Scholar
• Righetti M., Serbelloni P., Milani S., Ferrario G. Homocysteine‐lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 2006; 24: 379–86
   PubMed Web of Science ®Google Scholar
• Clarke R., Lewington S., Sherliker P., Armitage J. Effects of B‐vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia. Curr Opin Clin Nutr Metab Care 2007; 10: 32–9
   PubMed Web of Science ®Google Scholar
• Blom H. J., De Vriese A. S. Why are homocysteine levels increased in kidney failure? A metabolic approach. J Lab Clin Med 2002; 139: 262–8
   PubMedGoogle Scholar
• Guttormsen A. B., Ueland P. M., Svarstad E., Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997; 52: 495–502
   PubMedGoogle Scholar
• Yango A., Shemin D., Hsu N., Jacques P. F., Dworkin L., Selhub J., Bostom A. G. Rapid communication: L‐folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Kidney Int 2001; 59: 324–7
   PubMed Web of Science ®Google Scholar
• Bergesio F., Monzani G., Guasparini A., Ciuti R., Gallucci M., Cristofano C., Castrignano E., Cupisti A., Barsotti G., Marcucci R., Abbate R., Bandini S., Gallo M., Tosi P. L., Salvadori M. Cardiovascular risk factors in severe chronic renal failure: the role of dietary treatment. Clin Nephrol 2005; 64: 103–12
   PubMed Web of Science ®Google Scholar
• Siems W., Quast S., Carluccio F., Wiswedel I., Hirsch D., Augustin W., Kraemer K., Hampl H., Sommerburg O. Oxidative stress in cardio renal anemia syndrome: correlations and therapeutic possibilities. Clin Nephrol 2003; 60 Suppl 1: S22–30
   Google Scholar